Workflow
龙津药业(002750) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥5,901,760.59, a decrease of 77.64% compared to ¥26,388,422.34 in the same period last year[5] - The net profit attributable to shareholders was -¥4,079,872.65, showing an improvement of 9.17% from -¥4,491,776.72 year-on-year[5] - Total operating revenue for the current period is 5,901,760.59, a decrease of 77.7% compared to 26,388,422.34 in the previous period[19] - Net profit for the current period is -4,890,695.58, an improvement from -5,566,204.56 in the previous period[20] - Basic and diluted earnings per share for the current period are both -0.0102, slightly improved from -0.0112 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities was -¥12,849,141.89, a decline of 169.70% compared to -¥4,764,302.80 in the previous year[5] - Operating cash flow for the current period is -12,849,141.89, worsening from -4,764,302.80 in the previous period[22] - The company's cash and cash equivalents decreased from 261,742,130.25 CNY to 50,854,157.95 CNY, a decline of approximately 80.6%[15][16] - Cash and cash equivalents at the end of the period are 50,854,097.38, down from 129,653,249.19 in the previous period[23] - Total current assets decreased from 338,177,284.73 CNY to 311,106,917.55 CNY, a reduction of about 8%[16] - The total liabilities decreased from 80,185,043.61 CNY to 69,958,735.88 CNY, a decrease of approximately 12.5%[17] - The company's total assets decreased from 574,398,586.84 CNY to 555,151,183.53 CNY, a decline of about 3.4%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,091[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 39.40% of the shares, totaling 157,782,293 shares[11] Government Support and Subsidies - The company received government subsidies amounting to ¥846,338.40 during the reporting period[6] - Other income for the current period is 846,338.40, an increase from 677,867.89 in the previous period[20] Expenses and Costs - The company's sales expenses decreased by 83.84% to ¥2,796,905.35 due to the implementation of centralized procurement policies[9] - Total operating costs for the current period are 11,934,554.14, down 64.7% from 33,756,765.30 in the previous period[19] - Research and development expenses for the current period are 1,676,309.60, down from 1,992,368.82 in the previous period[19] Investment and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 556.62% to ¥219,437,991.06[9] - The company’s investment income decreased by 95.55% to ¥29,110.89, attributed to cash management products not maturing[9] - Investment activities generated a net cash flow of -197,329,574.98, compared to -86,299,874.27 in the previous period[23] Risks and Challenges - The company has received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing due to negative profits and revenue below ¥300 million[4] - The core product, Longjin® injection of Lampflower extract, is expected to face risks of declining sales and revenue due to the national centralized procurement policy starting in April 2025[14] Asset Changes - The company's retained earnings decreased from 18,950,761.77 CNY to 14,870,889.12 CNY, a decline of approximately 21.4%[17] - The total equity attributable to the parent company decreased from 470,459,142.64 CNY to 464,319,475.03 CNY, a reduction of about 1.4%[17] - The company's intangible assets increased by 51.35% to ¥50,465,817.98 due to new drug production approvals[9]